Stemtech Q1 Revenue Drops 47% to $463K, Net Loss Narrows Despite Sales Decline
Summary
Stemtech Corp reported a 46.7% year-over-year revenue decline to $462,957 for Q1 2026. Despite the significant sales drop, the company managed to narrow its net loss to $(1.25) million from $(1.45) million in the prior year, with diluted EPS loss improving to $(0.00). This follows the 10-Q filing earlier today, which broadly indicated a challenging quarter. The revenue decline was primarily due to constrained inventory, but management has initiated replenishment and secured financing. Cost reductions also contributed to the improved loss figures, offering a mixed but potentially stabilizing picture for the micro-cap company.
At the time of this announcement, STEK was trading at $0.00 on OTC in the Trade & Services sector, with a market capitalization of approximately $433.9K. The 52-week trading range was $0.00 to $0.03. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.